Also known as: regulatory RNA-targeting therapeutics
CAMP4 Therapeutics announced Nasdaq inducement stock option grants for newly hired employees in February and April 2026. The awards covered 51,000 shares in total and vest over four years.
CAMP4 Therapeutics appoints Michael MacLean to its Board of Directors as the company advances CMP-002 toward a Phase 1/2 trial for SYNGAP1-related disorder. The company also announced an inducement stock option grant of 8,000 shares at $3.85 per share to a new employee. CAMP4 is developing regulatory RNA-targeting therapeutics to upregulate gene expression for genetic diseases.
